Gastrin: growth enhancing effects on human gastric and colonic tumour cells.

por Watson, S., Durrant, L., Morris, D.
Publicado 1989

CD55 is over-expressed in the tumour environment

por Li, L, Spendlove, I, Morgan, J, Durrant, L G
Publicado 2001

Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I.

por Durrant, L. G., Watson, S. A., Hall, A., Morris, D. L.
Publicado 1991

Development of an ELISA to detect early local relapse of colorectal cancer.

por Durrant, L. G., Jones, H., Armitage, N. C., Baldwin, R. W.
Publicado 1989

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy

por Shehata, M, Mukherjee, A, Deen, S, Al-Attar, A, Durrant, L G, Chan, S
Publicado 2009

High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival

por Noble, P, Vyas, M, Al-Attar, A, Durrant, S, Scholefield, J, Durrant, L
Publicado 2013

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer

por Popple, A, Durrant, L G, Spendlove, I, Rolland, P, Scott, I V, Deen, S, Ramage, J M
Publicado 2012

Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies.

por Durrant, L. G., Robins, R. A., Ballantyne, K. C., Marksman, R. A., Hardcastle, J. D., Baldwin, R. W.
Publicado 1989

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression.

por Durrant, L. G., Ballantyne, K. C., Armitage, N. C., Robins, R. A., Marksman, R., Hardcastle, J. D., Baldwin, R. W.
Publicado 1987

Antigenicity of newly established colorectal carcinoma cell lines.

por Durrant, L. G., Robins, R. A., Pimm, M. V., Perkins, A. C., Armitage, N. C., Hardcastle, J. D., Baldwin, R. W.
Publicado 1986

Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.

por Durrant, L. G., Garnett, M. C., Gallego, J., Armitage, N. C., Ballantyne, K. C., Marksman, R. A., Hardcastle, J. D., Baldwin, R. W.
Publicado 1987

Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

por Pritchard-Jones, K, Spendlove, I, Wilton, C, Whelan, J, Weeden, S, Lewis, I, Hale, J, Douglas, C, Pagonis, C, Campbell, B, Alvarez, P, Halbert, G, Durrant, L G
Publicado 2005

Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention

por Knight, H., Jia, R., Ayling, K., Bradbury, K., Baker, K., Chalder, T., Morling, J.R., Durrant, L., Avery, T., Ball, J.K., Barker, C., Bennett, R., McKeever, T., Vedhara, K.
Publicado 2021

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

por Maxwell-Armstrong, C A, Durrant, L G, Buckley, T J D, Scholefield, J H, Robins, R A, Fielding, K, Monson, J R T, Guillou, P, Calvert, H, Carmichael, J, Hardcastle, J D
Publicado 2001

Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus

por Lande, R., Palazzo, R., Gestermann, N., Jandus, C., Falchi, M., Spadaro, F., Riccieri, V., James, E. A., Butera, A., Boirivant, M., Feldmeyer, L., Surbeck, I., Di Lucca, J., Stuber, F., Spinelli, F. R., Botti, E., Marinari, B., Bianchi, L., Pica, R., Cerbelli, B., Giannakakis, K., Auteri, S. E., Daniels, I., Durrant, L. G., Horstman, S., Costanzo, A., Romero, P., Alessandri, C., Conti, F., Valesini, G., Gilliet, M., Chizzolini, C., Frasca, L.
Publicado 2020